About InforMax
InforMax is a company based in Bethesda (United States) founded in 1990 by Alex Titomirov was acquired by Invitrogen in October 2002. InforMax has raised $4 million across 1 funding round from investors including Invitrogen. InforMax operates in a competitive market with competitors including DNAnexus, Cytel, Verge Genomics, Genomics and Seven Bridges Genomics, among others.
- Headquarter Bethesda, United States
- Founders Alex Titomirov
- Stage Public
- SectorsHealthcare
- Website informaxinc.com
- Acquired by Invitrogen (Oct 2002)
- Total Equity Funding$4M (USD)
in 1 rounds
- Latest Funding Round$4M (USD), Series A
Jul 1999
- Investors
- Acquired byInvitrogen
(Oct 2002)
Funding Insights of InforMax
InforMax has successfully raised a total of $4M through 1 strategic funding round. The most recent funding activity was a Series A round of $4 million completed in July 1999. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $4M
- Total Rounds 1
- Last Round Series A — $4M
- First Round $4M
(Jul 1999)
All 1 funding rounds of InforMax with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 1999 | $4M | Series A | – | – | – |
1 investors in total: 1 institutional.
Investors in InforMax
InforMax has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Invitrogen.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Provider of scientific instruments, services, and consumables | 1987 | invitrogen.com | Carlsbad, United States |
Investor details for InforMax
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of InforMax
1 people are tracked at InforMax (1 in leadership).
| Name | Role | Group |
|---|---|---|
Alex Titomirov | Founder | Leadership |
Complete people profiles for InforMax
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of InforMax
4 dated milestones of InforMax across 12 years, from founding to its latest funding, stage changes and deals.
- Founded InforMax is founded.
- Funding First funding round of $4.0M.
- IPO Lists on the stock exchange (IPO).
- Exit Acquired by Invitrogen.
Competitors of InforMax
InforMax operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as DNAnexus, Cytel, Verge Genomics, Genomics and Seven Bridges Genomics, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| dnanexus.com | 2009 | Mountain View, United States | $472.55M | 143 | Cloud-based genome informatics and data management are provided. | |
| cytel.com | 1987 | Cambridge, United States | $2M | 509 | Data analysis and statistical solutions are provided for life sciences. | |
| vergegenomics.com | 2015 | San Francisco, United States | $134.5M | 38 | Neurodegenerative disease drugs are developed using computational genomics. | |
| genomics.com | 2014 | Oxford, United Kingdom | $115.54M | – | Genomic risk assessment and prevention platform is provided. | |
| sevenbridges.com | 2009 | Cambridge, United States | $113M | 112 | Cloud-based platform to analyze, store, and act on genomic data. | |
| metagenomi.co | 2016 | Berkeley, United States | $376.37M | – | Next-generation gene editing tools are developed for drug enhancement. | |
| octant.bio | 2017 | Los Angeles, United States | $110M | 63 | Human cell interaction platform is provided for drug discovery. | |
| relationrx.com | 2020 | London, United Kingdom | $80.25M | 12 | AI-based tools for drug discovery are provided to researchers. | |
| turbine.ai | 2015 | Budapest, Hungary | $36.68M | – | Turbine is recognized for its AI-driven cell simulation platform. |
Detailed competitors of InforMax
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Similar companies to InforMax
10 companies that operate in the same segment as InforMax (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 265 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about InforMax
InforMax was founded in 1990 and raised its 1st funding round 9 years after it was founded.
InforMax is headquartered in Bethesda, United States. It is registered at Bethesda, Maryland, United States.
InforMax is a funded company, having raised a total of $4M across 1 funding round to date. The company's 1st funding round was a Series A of $4M, raised on Jul 1999.
InforMax was founded in 1990 and operates as a subsidiary of Life Technologies Corporation under Thermofisher. Informatics software for the life sciences sector is developed by the company, focusing on the management, analysis, and interpretation of genomic, proteomic, and biomolecular data. Key offerings include Vector NTI Suite for sequence research visualization and GenoMax for handling large datasets. The company is based in Bethesda, United States.
InforMax's top competitors include DNAnexus, Cytel and Relation Therapeutics.
InforMax has 1 investor. Key investors include Invitrogen.
Yes. InforMax was acquired by Invitrogen in October 2002.